Analyzing the Estimated Cost of B-VEC for Dystrophic Epidermolysis Bullosa Treatment
The following is a summary of "Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa," published in the January 2024 issue of Dermatology by Raymakers, et al. The approval of the first topical gene therapy, beremagene geperpavec (B-VEC),...